F10 and atrial fibrillation: The ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial was a double blind randomized control trial to assess the efficacy of rivaroxaban 20 mg daily in comparison to dose adjusted warfarin in patients with non-valvular atrial fibrillation [25].